Margaret M. Zaleska, PhD.

Dr. Zaleska serves as a consultant and offers NTS expertise in in vivo models of central nervous system injury and in the bench- to- clinic translational strategies. Dr. Zaleska has over 20 year experience in developing compounds for neurological indications in the pharmaceutical industry including Wyeth and Pfizer Inc. She led numerous drug discovery programs for small molecules and biologics from target inception and drug candidate validation to clinical development. While at Wyeth, she successfully led five Projects Teams to deliver diverse drug candidates from discovery to clinical development for the treatment of stroke. Most recently, as a Portfolio Lead at Pfizer Neuroscience Unit, Dr. Zaleska led the alliance with the CHDI Foundation from the preclinical strategy to clinical development planning, and regulatory documentation submission for PDE10 inhibitor which entered Phase II clinical trial. Dr. Zaleska has been a Standing member of the Neurological Sciences and Disorders Study Section Committee and the NINDS Special Emphasis Panel Scientific Review Group. She is also a member of Michael J. Fox Foundation Therapeutic Pipeline Projects’ Review Board.

Earlier in her career Dr. Zaleska held research faculty position at the Department of Biochemistry and Biophysics at the University of Pennsylvania School of Medicine in Philadelphia. Dr. Zaleska received her MS in Biochemistry from the University of Warsaw, Poland and Ph.D. in Neuroscience from the Polish Academy of Sciences.